Nardilysin is a promising biomarker for the early diagnosis of acute coronary syndrome

Chen, Po‐Min; Ohno, Mikiko; Hiwasa, Takaki; Nishi, Kiyoto; Saijo, Sayaka; Sakamoto, Jiro; Morita, Yusuke; Matsuda, Shintaro; Watanabe, Shin; Kuwabara, Yasuhide; Ono, Koh; Imai, Michitaka; Inoue, Katsumi; Murai, Tatsuya; Inada, Takao; Tanaka, Masaru; Kita, Toru; Kimura, Takeshi; Nishi, Eiichiro

doi:10.1016/j.ijcard.2017.04.047

Cited by 23 publications

(30 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NRDC in macrophages regulates arthritis via the control of TNFa secretion because the macrophage-specific deletion of NRDC markedly ameliorated arthritis (31). We also demonstrated that inflammatory cells infiltrating the infarcted myocardium strongly express NRDC (25). However, clinical data from this study do not strongly support this hypothesis because preoperative C-reactive protein levels in ICC patients did not correlate with serum NRDC levels (data not shown).…”

Section: Discussionmentioning

confidence: 67%

“…Serum was isolated from whole blood and stored at À80 C until analyzed. To quantify serum NRDC levels, an enzyme-linked immunosorbent assay (ELISA) was performed according to a previously described method (25). Briefly, to establish a sandwich ELISA system, all combinations of the 7 monoclonal antibodies for NRDC were tested, and the optimum combination of clone #231 for coating and #304 for detection was selected.…”

Section: Measurement Of Serum Nrdc Levelsmentioning

confidence: 99%

See 1 more Smart Citation

Serum Nardilysin, a Surrogate Marker for Epithelial–Mesenchymal Transition, Predicts Prognosis of Intrahepatic Cholangiocarcinoma after Surgical Resection

Hatano

Kasai

Fuji

et al. 2019

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

Purpose: Few studies have investigated prognostic biomarkers in patients with intrahepatic cholangiocarcinoma (ICC). Nardilysin (NRDC), a metalloendopeptidase of the M16 family, has been suggested to play important roles in inflammation and several cancer types. We herein examined the clinical significance and biological function of NRDC in ICC. Experimental Design: We measured serum NRDC levels in 98 patients with ICC who underwent surgical resection in two independent cohorts to assess its prognostic impact. We also analyzed NRDC mRNA levels in cancerous tissue specimens from 43 patients with ICC. We investigated the roles of NRDC in cell proliferation, migration, gemcitabine sensitivity, and gene expression in ICC cell lines using gene silencing. Results: High serum NRDC levels were associated with shorter overall survival and disease-free survival in the primary (n ¼ 79) and validation (n ¼ 19) cohorts. A correlation was observed between serum protein levels and cancerous tissue mRNA levels of NRDC (Spearman r ¼ 0.413; P ¼ 0.006). The gene knockdown of NRDC in ICC cell lines attenuated cell proliferation, migration, and tumor growth in xenografts, and increased sensitivity to gemcitabine. The gene knockdown of NRDC was also accompanied by significant changes in the expression of several epithelial-mesenchymal transition (EMT)-related genes. Strong correlations were observed between the mRNA levels of NRDC and EMT-inducing transcription factors, ZEB1 and SNAI1, in surgical specimens from patients with ICC. Conclusions: Serum NRDC, a possible surrogate marker reflecting the EMT state in primary tumors, predicts the outcome of ICC after surgical resection.

show abstract

Section: Discussionmentioning

confidence: 67%

Section: Measurement Of Serum Nrdc Levelsmentioning

confidence: 99%

Serum Nardilysin, a Surrogate Marker for Epithelial–Mesenchymal Transition, Predicts Prognosis of Intrahepatic Cholangiocarcinoma after Surgical Resection

Hatano

Kasai

Fuji

et al. 2019

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…We examined the levels of antibodies against the bPRCP-214 peptide in sera of HDs and patients with DM or CVD, using the supersensitive and stable AlphaLISA method [23][24][25][26][27][28][29][30][31]. All serum samples were obtained from Chiba University Hospital.…”

Section: Elevation Of Serum Antibody Levels Against Prcp In Patients mentioning

confidence: 99%

“…We also identified the following autoantibody-recognized antigens by recombinant cDNA expression cloning (SEREX) method or protein array method: TACSTD2 [12], TRIM21 [13], SLC2A1 [14], MKRN1 [15], ECSA [16], and CCNL2 [17] in esophageal squamous cell carcinoma; FIR/PUF60 in colon carcinoma [18]; SH3GL1 [19] and filamin C [20] in low-grade glioma; TLN1 in multiple sclerosis [21]; RPA2 [22] and SOSTDC1 [23] in ischemic stroke; NRD1 in acute coronary syndrome [24]; TUBB2C [25], GADD34 [26], and adiponectin [27] in DM; COPE in obstructive sleep apnea [28]; and ATP2B4 [29], BMP-1 [22,29], DHPS [30], and SH3BP5 [31] in arteriosclerosis-related diseases.…”

Section: Introductionmentioning

confidence: 99%

Association of Serum Anti-Prolylcarboxypeptidase Antibody Marker with Atherosclerotic Diseases Accompanied by Hypertension

Zhang¹,

Wang²,

Mine³

et al. 2017

J Mol Biomark Diagn

View full text Add to dashboard Cite

show abstract

“…Despite of the increased successful treatment rates of STEMI patients, they are still confronted with worse prognosis after the incidence of STEMI, including heart failure, recurrence of STEMI, and other complications (3). Multiple tools have been developed to evaluate the risk and predict the prognosis of patients with STEMI, including comprehensive score system and biomarkers, such as SYNTAX score (4), glycated hemoglobin (5), Nardilysin (6) and other biomarkers. However, relative less accuracy and focus on early prognosis have limited the application of those biomarkers and risk stratification, which necessitates more studies to evaluate the value of novel biomarkers in predicting the long-term prognosis of STEMI.…”

Section: Introductionmentioning

confidence: 99%

Novel biomarker of Cysteine-rich angiogenic inducer 61 (Cyr61) predicts long-term outcome of ST-elevation myocardial infarction

Xiang

Mao

Tang

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Cysteine-rich angiogenic inducer 61 (Cyr61) is a matricellular protein participating in the angiogenesis, inflammation, and fibrotic tissue repair. Previous study has proven its value in diagnosing and risk stratification of ST-elevation myocardial infarction (STEMI). However, there is no study focusing on Cyr61 and the long-term outcome of STEMI. Methods: A total of 426 patients diagnosed with STEMI were enrolled in this study. Blood sample was acquired 24 hours after the admission. The patients were required long-term follow-up after the discharge, when primary endpoint of all-cause death and secondary endpoint of cardiac complications were observed. Cox hazard ratio model and survival analysis were used to compare the risk of patients with higher level and lower level of Cyr61. Results: We conducted an average of (48.4 ± 17.8) months of follow-up, during which a total of 28 deaths happened (6.6%), while 106 episodes of secondary endpoints occurred (24.9%). Patients with higher quartile (Q4) Cyr61 were at higher risk of death [HR 3.404 95%CI (1.574-7.360), P<0.001] when compared with lower three quartiles (Q1-Q3) Cyr61. In terms of secondary endpoints, patients with Q4 Cyr61 were subject to 4.718 [95%CI (3.189-6.978) , P<0.001] times of risk compared with Q1-Q3 Cyr61. Conclusions: For STEMI Patients, those with increased Cyr61 have higher risk of all-cause death and cardiac complications. Therefore, Cyr61 may be a useful tool in predicting the long-term prognosis of STEMI.

show abstract

Nardilysin is a promising biomarker for the early diagnosis of acute coronary syndrome

Abstract: NRDC is a promising biomarker for the early detection of ACS, even in UA patients without elevation of necrosis markers.

Cited by 23 publications

References 23 publications

Serum Nardilysin, a Surrogate Marker for Epithelial–Mesenchymal Transition, Predicts Prognosis of Intrahepatic Cholangiocarcinoma after Surgical Resection

Serum Nardilysin, a Surrogate Marker for Epithelial–Mesenchymal Transition, Predicts Prognosis of Intrahepatic Cholangiocarcinoma after Surgical Resection

Association of Serum Anti-Prolylcarboxypeptidase Antibody Marker with Atherosclerotic Diseases Accompanied by Hypertension

Novel biomarker of Cysteine-rich angiogenic inducer 61 (Cyr61) predicts long-term outcome of ST-elevation myocardial infarction

Contact Info

Product

Resources

About